About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clinical Evaluation of LeSoleil Against COVID-19

By: ACN Newswire
Guangzhou, China, Jan 6, 2022 - (ACN Newswire) - Since February 2020, when Suntrap Life Technologies Ltd established a COVID-19 project for drug discovery, the Suntrap research team has evaluated and prudently predicted the characteristics of COVID-19. Utilizing the proprietary S-CPDD drug design and discovery system and IDDNU(R) (International Drug Design Network Union) platforms in accordance with scientific laws of drug discovery, Suntrap's research team has tracked and analyzed the pathological characteristics, clinical needs, pathogenesis research and social demands of patients. In terms of the determination of the direction of drug research and development (R&D), COVID-19 drug related targets acquisition, molecular design and screening, and preclinical verification, the new drug R&D in the Suntrap research team is fully guided by clinical values. It will be standard for the Suntrap team to quickly transform biomedical research into industrial products, and ultimately develop new pharmaceutical products that benefit the public, thus realizing the fundamental significance of new drug R&D.

The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.

In May 2020, the Suntrap research team identified a lead compound "LeSoleil-T" through a series of bioassays, which showed anti-coronavirus activities with multi-targets inhibition effects. Further studies revealed that the multi-targets design properties of LeSoleil-T could meet the demands of broad-spectrum anti-coronavirus.

In view of the inhibitory effects of LeSoleil-T against SARS-CoV-2, the pharmacological mechanisms of LeSoleil-T were explored through a series of experimental assays. The results showed that LeSoleil-T has pharmacological effects in the treatment of SARS-CoV-2 infection as the following: broad-spectrum anti-coronavirus inhibitory effects, anti-inflammatory effects, neuron protections, delay and reversal of tissue fibrosis.

Based on the above results, the Suntrap team has obtained the Chinese invention patent authorization for the broad-spectrum anti-coronavirus in January 2021, and has filed international patent applications through the PCT, and applied for patent protection in many countries and regions.

According to clinical investigations, upon SARS-CoV-2 infection, the levels of the neutrophil count, D-dimer, blood urea and creatinine in patients will increase continuously, while the count of lymphocytes will continue to decline until death. Suntrap team found that LeSoleil-T could eliminate inflammation induced by SARS-CoV-2 infection. The anti-inflammatory effects of LeSoleil-T are mainly to inhibit proinflammatory factor expression and reduce oxidative stress responses. Firstly, LeSoleil-T can inhibit neutrophil aggregation to reduce the production of 4-HNE (4-hydroxynonenal) by oxidative stress response, which leads to the reduction of the lipid peroxidation end-product formation, and finally, contribute to its anti-inflammatory activity. Secondly, LeSoleil-T directly inhibits the expression of proinflammatory factors (e.g., Tnf-alpha, IL-1beta, IL-6, Mcp-1, Mcp-2, and Mip-1alpha). Finally, it activates the interactions among PGC-1alpha (Peroxisome proliferator-activated receptor-gamma coactivator), Nrf1 (Nuclear Respiratory Factor 1) and Nrf2 (Nuclear Respiratory Factor 2) to regulate the mitochondrial synthesis, respiration, and various antioxidant enzymes. Meanwhile, the Nrf2/ARE (antioxidant response element) complex scavenges free radicals by regulating the expression of HO-1 (heme oxygenase-1).

Based on the clinical symptoms and pathogenic mechanism of patients infected with SARS-CoV-2, the Suntrap research team optimized and developed different clinical protocols. The basic formulation was completed in November 2020.

The LeSoleil broad-spectrum anti-coronavirus protective and therapeutic spray is portable and easy to use. It effectively prevents healthy people from infection and blocks the spread of SARS-CoV-2 from asymptomatic and mild COVID-19 patients. LeSoleil broad-spectrum anti-coronavirus protective and therapeutic spray can cope with the prevention and treatment of SARS-CoV-2 and variant strains (e.g., Delta and Omicron.). In addition, the preclinical study conducted by the Suntrap team revealed that LeSoleil can also be used for upper respiratory tract infections caused by influenza viruses and mutant strains (e.g., H1N1, H5N1, H7N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H10N8). The new corresponding symptoms still need to be verified by clinical research.

The COVID-19 pandemic has continued for nearly two years. Mutant strains are constantly emerging, and the global incidence rate continues to rise. To date, the Suntrap research team has achieved a certain degree of breakthrough in the design of multi-target anti-coronavirus drugs. It is necessary to accelerate the clinical verification and strengthen cooperation. To further in-depth clinical research of LeSoleil anti-SARS-CoV-2 drugs, and deter COVID-19 as an obstacle for social stability, economic development and human health, Suntrap recruits qualified clinical research institutions around the world to carry out clinical evaluation studies on the efficacy of the LeSoleil broad-spectrum anti-coronavirus drug series against mutant strains of SARS-CoV-2.

Consult www.suntrap.com or search for "IDDNU" and "Suntrap" for related reports.

Full release at https://www.suntrap.com/newsinfo/586652.html?templateId=182930

Contact:
Zoe Zhou, Suntrap Life Technologies Ltd
E: info@suntrap.com
T: +86-20-23889990
U: https://www.suntrap.com

Source: Suntrap Life Technologies Ltd

Copyright 2022 ACN Newswire . All rights reserved.

More News

View More
3 Heavily Shorted Stocks That Could Pop on Rate Cuts
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers ETSY SMR SOUN
Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
Via MarketBeat
Tickers AVGO META
PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Via MarketBeat
Tickers PEP
Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been
Via MarketBeat
Tickers DKNG
Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom
Via MarketBeat
Tickers BUD STZ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.